SBIR Road Tour
Wednesday, June 20, 2018, 7:00 am – 5:00 pm
Ohio State University, Columbus, Ohio

The SBIR Road Tour is coming to Columbus, OH on Wednesday, June 20, 2018, to convey the non-dilutive technology funding opportunity provided through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.

The day will consist of panel discussions, networking and meeting with individual program managers from participating government agencies representing $2.5 billion early stage funding.  This one-day event brings together these agencies, technology entrepreneurs and state innovation ecosystem members.

Attendees will learn:

• How to access local and state resources available to innovators, researchers and technology entrepreneurs
• Priorities for SBIR agencies’ funding
• The do’s and don’ts of a successful funding proposal
• How to best utilize local funding resources to improve likelihood of success

Attendees will also be able to reserve a one-on-one meeting with SBIR/STTR Program Managers from various agencies.

For more information and to register, click here.

Registration is open through June 13, 2018.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

All applications for PRMRP funding must specifically address at least one of the Topic Areas as directed by Congress and must be directly relevant to the healthcare needs of military Service members, Veterans, and/or beneficiaries.  If the proposed research does not specifically address at least one of the FY18 PRMRP Topic Areas, the Government will administratively withdraw the application.  The Government reserves the right to reassign the application’s Topic Area if submitted under an inappropriate Topic Area.  The FY18 PRMRP Topic Areas are listed below.

• Acute Lung Injury
• Antimicrobial Resistance
• Arthritis
• Burn Pit Exposure
• Cardiomyopathy
• Cerebellar Ataxia
• Chronic Migraine and Post-Traumatic Headache
• Chronic Pain Management
• Congenital Heart Disease
• Constrictive Bronchiolitis
• Diabetes
• Dystonia
• Eating Disorders
• Emerging Infectious Diseases
• Endometriosis
• Epidermolysis Bullosa
• Focal Segmental Glomerulosclerosis
• Fragile X
• Frontotemporal Degeneration
• Guillain-Barré Syndrome
• Hepatitis B and C
• Hereditary Angioedema
• Hydrocephalus
• Immunomonitoring of Intestinal Transplants
• Inflammatory Bowel Diseases
• Interstitial Cystitis
• Lung Injury
• Malaria
• Metals Toxicology
• Mitochondrial Disease
• Musculoskeletal Disorders
• Myotonic Dystrophy
• Non-Opioid Pain Management
• Nutrition Optimization
• Pancreatitis
• Pathogen-Inactivated Blood Products
• Post-Traumatic Osteoarthritis
• Pressure Ulcers
• Pulmonary Fibrosis
• Respiratory Health
• Rett Syndrome
• Rheumatoid Arthritis
• Scleroderma
• Sleep Disorders
• Spinal Muscular Atrophy
• Sustained-Release Drug Delivery
• Tinnitus
• Tissue Regeneration
• Tuberculosis
• Vaccine Development for Infectious Diseases
• Vascular Malformations
• Women’s Heart Disease

The mission of the PRMRP is to encourage, identify, and select military health-related research of exceptional scientific merit. Relevance to the healthcare needs of military Service members, Veterans, and their family members is a key feature of each FY18 PRMRP award mechanism.

http://cdmrp.army.mil/funding/prmrp

Discovery Award – Letter of Intent due June 14, 2018

• Postdoctoral fellow or clinical fellow (or equivalent) and above.
• Supports the exploration of a highly innovative new concept or untested theory in the Topic Area(s) of interest.
• Not intended to support the logical progression of an already established line of questioning.
• Clinical trials will not be funded.
• Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s).
• Maximum of $200,000 for direct costs (plus indirect costs)
• Maximum period of performance is 18 months

Focused Program Award – Preproposal due June 19, 2018

• Lead PI: Full Professor level or above (or equivalent)
• Project leads: Assistant Professor level or above (or equivalent)
• Preproposal submission is required; application submission is by invitation only.
• Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal in the Topic Area(s) of interest.
• Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
• Projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.
• Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.
• Maximum of $10 million for total costs (includes direct and indirect costs)
• Maximum period of performance is 4 years

Investigator-Initiated Research Award – Preproposal due June 12, 2018

• Assistant Professor level or above (or equivalent)
• Preproposal submission is required; application submission is by invitation only.
• Supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.
• Partnering PI Option available.
• Clinical trials will not be funded.
• Maximum of $1.2 million for direct costs (plus indirect costs)
• Maximum of $1.5 million for direct costs (plus indirect costs) for applications including a Partnering PI Option
• Maximum period of performance is 3 years

Technology/ Therapeutic Development Award – Preproposal due June 12, 2018 

• Assistant Professor level or above (or equivalent)
• Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life in the Topic Area(s) of interest.
• Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
• Clinical trials will not be funded.
• Preproposal submission is required; application submission is by invitation only.
• Maximum of $3.0 million for direct costs (plus indirect costs)
• Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Grants.gov. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The Ray C. Anderson Foundation is a private family foundation committed to advancing the legacy of its namesake by supporting environmental sustainability initiatives. Ray’s five grandchildren, along with their spouses, comprise the NextGen Committee of the Foundation, which makes recommendations to the board of trustees for worthwhile grants and initiatives. In 2018, the NextGen Committee has decided to focus its philanthropic efforts on programs that help reverse global warming.

To advance this mission, the NextGen program has issued a Request for Proposals for a single grant of $90,000 to fund work in the 2019 calendar year by an existing or new program that will measurably reduce the concentration of greenhouse gases in the atmosphere as measured by metric tons (or “tonnes”) of carbon dioxide equivalent (CO2e), either by preventing the emission of those gases or by sequestering gases presently in the atmosphere.

To be eligible, applicants must be considered tax exempt under Section 501(c)(3) of the United States Internal Revenue Code.

Those interested in applying for the grant should visit the grant web page to review the proposal guidelines and submit their proposal.

Application Deadline:  July 11, 2018

For more information, please visit www.raycandersonfoundation.org